BIOCYTOGEN-B (02315) rose more than 8%, with the stock up 8.15% to HK$48.86 at the time of writing. The trading volume was HK$19.20 million. The increase follows the company's release of its 2025 performance forecast, which anticipates revenue of approximately RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to reach RMB 173 million, surging 416.37% compared to the previous year. After adjusting for non-recurring gains and losses, net profit attributable to owners is projected to be RMB 116 million, up 405.39% year-on-year. During the reporting period, the company maintained its strategy of driving growth through innovation, building core technological advantages via sustained high research and development investment, and ensuring operations remain at a high gross margin level. Guolian Minsheng Securities noted that as of the first half of 2025, the company had signed approximately 280 drug development, licensing, or transfer agreements with around 120 pharmaceutical companies, including about 80 new agreements added in the first half of 2025. In February 2026, IDEAYA's B7H3/PTK7 ADC candidate drug IDE034, licensed from BIOCYTOGEN-B, completed enrollment of the first patient in its Phase 1 clinical trial. IDEAYA will pay the company a milestone payment of US$5 million, with the total potential value of the collaboration reaching up to US$406.5 million. The securities firm believes that as the number of licensing projects grows and clinical progress continues, the antibody development business will contribute increasingly to earnings, opening up long-term growth opportunities for the company.
Comments